Company Profile
Lineage Cell Therapeutics Stock Price, News & Analysis
- Ticker:
- LCTX
- Exchange:
- AMEX
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
1.21 USD (-5.47%)
Close
Last updated: July 13, 2026 at 00:00
319.1M USD
Market cap
Why the stock is moving
LCTX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Lineage Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
Geographic Base and Sector Classification
Headquartered in the United States and listed on 美国证券交易所, Lineage Cell Therapeutics sits inside the cell therapy universe where trial execution and regulatory timing can change the investment case quickly.
Business Model Characteristics
Lineage Cell Therapeutics follows a platform-led model where readouts, manufacturing progress, and commercialization milestones matter as much as the initial science. The market tends to reprice the stock quickly whenever adoption, safety, or label-expansion signals improve.
Position Within the Biotechnology Landscape
Compared with larger diversified biotech peers, Lineage Cell Therapeutics sits at the high-catalyst end of the landscape, where cell therapy names can move sharply on data, approvals, and launch milestones.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 03
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lineage Cell Therapeutics (LCTX)?
Lineage Cell Therapeutics (LCTX) most recently closed at 1.21 USD, a -5.47% move versus the previous session.
What is the market cap of Lineage Cell Therapeutics (LCTX)?
Lineage Cell Therapeutics currently has a market capitalization of 319.1M USD on BioPharmSignal.
What does Lineage Cell Therapeutics do?
Lineage Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
On which exchange is LCTX stock listed?
Lineage Cell Therapeutics (LCTX) is associated with AMEX, United States, Biotechnology.
What is Lineage?
Lineage Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases.
Which conditions is Lineage Cell Therapeutics targeting with Lineage?
Lineage Cell Therapeutics is associated with oncology based on its company overview and current catalyst commentary.
What is Cell?
Lineage Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases.
What is Therapeutics?
Lineage Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases.